Takotsubo cardiomyopathy: a novel beta-adrenergic blocker withdrawal syndrome

2013 ◽  
Vol 154 (7) ◽  
pp. 267-271 ◽  
Author(s):  
János Tomcsányi ◽  
Kinga Jávor ◽  
Hrisula Arabadzisz ◽  
András Zsoldos ◽  
Vince Wagner ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Takotsubo Cardiomyopathy ◽  
Cardiac Dysfunction ◽  
Drug Withdrawal ◽  
Beta Blockers ◽  
Stress Cardiomyopathy ◽  
Abrupt Withdrawal ◽  
Adrenergic Blocker ◽  
Artery Disease ◽  
Long Acting

The authors describe two cases of takotsubo cardiomyopathy developing after an abrupt withdrawal of carvedilol and bisoprolol. Takotsubo or stress cardiomyopathy is characterized by acute and reversible cardiac dysfunction without coronary artery disease. It is triggered by acute emotional or physical stress, drugs or drug withdrawal. The immediate discontinuation of the long acting vasodilator beta-blocker, carvedilol has not yet been described to cause takotsubo cardiomyopathy. The authors recommend cautious withdrawal of beta-blockers. Orv. Hetil., 2013, 154, 267–271.

Suppression Of Platelet Aggregation By A New Beta-Adrenergic Blocker

1981 ◽  
Author(s):  
M Small ◽  
J T Douglas ◽  
Morna Orr ◽  
G D O Lowe ◽  
C D Forces ◽  
...  
Keyword(s):  
Platelet Aggregation ◽  
Blood Viscosity ◽  
Beta Blockers ◽  
Protective Action ◽  
Plasma Viscosity ◽  
Significant Inhibition ◽  
Variable Effect ◽  
Adrenergic Blocker ◽  
Artery Disease ◽  
Long Acting

Beta-blockers have been reported to have a variable effect on a number of haemostatic parameters. In view of their possible protective action in coronary artery disease, we studied the effect of the new long-acting beta-blocker, carteolol, on platelet function, coagulation and blood viscosity in 10 healthy male volunteers. Following carteolol (5 mg. orally) blood was taken at 2, 5 and 24 hours and we were able to demonstrate a significant inhibition of platelet aggregation to ADP, adrenaline and collagen (p< 0.05) at 5 hours post ingestion, but not at 2 or 24 hours. Platelet release as measured by plasma levels of beta-thromboglobulin, platelet count, fibrinopeptide A, whole blood viscosity and plasma viscosity was also unaltered.

scholarly journals Role of Selected miRNAs as Diagnostic and Prognostic Biomarkers in Cardiovascular Diseases, Including Coronary Artery Disease, Myocardial Infarction and Atherosclerosis

2021 ◽  
Vol 8 (2) ◽  
pp. 22
Author(s):  
Rashid Mir ◽  
Imadeldin Elfaki ◽  
Naina Khullar ◽  
Ajaz Ahmad Waza ◽  
Chandan Jha ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Cardiovascular Diseases ◽  
Cardiac Dysfunction ◽  
Heart Diseases ◽  
Prognostic Biomarkers ◽  
Apoptotic Bodies ◽  
Artery Disease

Cardiovascular diseases are the leading cause of death worldwide in different cohorts. It is well known that miRNAs have a crucial role in regulating the development of cardiovascular physiology, thus impacting the pathophysiology of heart diseases. MiRNAs also have been reported to be associated with cardiac reactions, leading to myocardial infarction (MCI) and ultimately heart failure (HF). To prevent these heart diseases, proper and timely diagnosis of cardiac dysfunction is pivotal. Though there are many symptoms associated with an irregular heart condition and though there are some biomarkers available that may indicate heart disease, authentic, specific and sensitive markers are the need of the hour. In recent times, miRNAs have proven to be promising candidates in this regard. They are potent biomarkers as they can be easily detected in body fluids (blood, urine, etc.) due to their remarkable stability and presence in apoptotic bodies and exosomes. Existing studies suggest the role of miRNAs as valuable biomarkers. A single biomarker may be insufficient to diagnose coronary artery disease (CAD) or acute myocardial infarction (AMI); thus, a combination of different miRNAs may prove fruitful. Therefore, this review aims to highlight the role of circulating miRNA as diagnostic and prognostic biomarkers in cardiovascular diseases such as coronary artery disease (CAD), myocardial infarction (MI) and atherosclerosis.

Treatment of ischemic heart disease in women during the pathological menopause

1982 ◽  
Vol 63 (3) ◽  
pp. 15-17
Author(s):  
E. V. Tsybulina ◽  
L. A. Emelyanova
Keyword(s):  
Coronary Artery Disease ◽  
Heart Disease ◽  
Comparative Analysis ◽  
Coronary Artery ◽  
Ischemic Heart Disease ◽  
Beta Blockers ◽  
Ischemic Heart ◽  
Myocardial Dystrophy ◽  
Artery Disease ◽  
Antianginal Drugs

A comparative analysis of the effectiveness of antianginal drugs (papaverine, persantine, intensain, nitrong, anaprilin) in combination with climacteric myocardial dystrophy in women was carried out. The data obtained make it possible to recommend beta-blockers (anaprilin, obzidan) for the treatment of coronary artery disease in women against the background of pathological menopause for wider use.

scholarly journals Purchases of medical therapy recommended for coronary artery disease before and after elective revascularisation

2019 ◽  
Vol 76 (1) ◽  
pp. 81-88
Author(s):  
Jari Heiskanen ◽  
Juha Hartikainen ◽  
Janne Martikainen ◽  
Heikki Miettinen ◽  
Mikko Hippeläinen ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Medical Therapy ◽  
Coronary Bypass ◽  
University Hospital ◽  
Blocking Agents ◽  
Before And After ◽  
Artery Disease ◽  
Long Acting ◽  
Cabg Patients

Abstract Aims We studied the purchases of medical therapy recommended for coronary artery disease patients before and after elective revascularisation (percutaneous coronary intervention (PCI) or coronary bypass grafting (CABG)). Methods All patients who underwent an elective PCI (N = 1557) or CABG (N = 1768) at the Heart Center, Kuopio University hospital between 2007 and 2014 were included. Data were collected from the hospital’s coronary register and national registers, and obtained for 3 years before and 1 year after the revascularisation. Results Altogether 85.2% of PCI patients and 88.1% of CABG patients had purchased lipid-modifying agents before the procedure, and 94.9% and 96.8% during the post-procedure follow-up year, respectively. Beta-blocking agents were purchased by 84.9% of PCI patients before and by 87.9% after the procedure and by 86.3% of CABG patients before and 97.1% after the operation. Of PCI patients, 64.3% had purchased organic long-acting nitrates before the procedure and 54.4% also after the procedure. Among CABG patients, the purchase of organic long-acting nitrates fell from 59.7% before to 10.1% after the operation. The use of ADP receptor blocking agents increased in PCI patients (26.3 to 83.9%) and the use of warfarin in CABG patients (9.4 to 21.3%). Medication purchases were more common among those who had greater use of hospital services before and after the procedures. Conclusions In both PCI and CABG patients, the use of medical therapy before and after revascularisation procedure complied with current guidelines. Purchases of long-acting nitrates were common in the PCI group even after the procedure.

Sign in / Sign up

Export Citation Format

Share Document